GlassScriptPhysician profile
Yi Chun Lai
NPI 1225499148
$4,942.07
in general payments reported to CMS, 2019-2025
28 companies · $2,274 in 2025
The $2,274 reported for 2025 was more than what 79% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $354 · 2023: $844 · 2024: $1,469 · 2025: $2,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,473 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,472.69 |
| Education | $115.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $930.08 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $865.18 | 2020-2025 | |
| Janssen Biotech, INC. | $551.87 | 2020-2025 | Tremfya |
| Pfizer INC. | $440.66 | 2024-2025 | |
| Galderma Laboratories, L.P. | $375.74 | 2020-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $230.61 | 2023-2025 | Zoryve |
| Incyte Corporation | $198.44 | 2023-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $195.94 | 2020-2025 | Dupixent |
| Amgen INC. | $179.02 | 2023-2025 | Otezla, Otezla, Enbrel |
| Lilly USA, LLC | $154.68 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $129.65 | 2023-2025 | Adbry, Anzupgo |
| Ucb, INC. | $102.25 | 2024-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $83.58 | 2023-2025 | Ilumya |
| Organon LLC | $74.48 | 2025 | |
| Dermavant Sciences, INC. | $62.49 | 2024 | Vtama |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $57.03 | 2020-2023 | |
| Biofrontera INC. | $52.76 | 2020-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Mayne Pharma Commercial LLC | $49.76 | 2023 | |
| Convatec INC. | $49.24 | 2023-2025 | |
| Kerecis Limited | $22.01 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Organogenesis INC. | $21.56 | 2025 | Affinity |
| E.R. Squibb & Sons, L.L.C. | $20.19 | 2024 | Sotyktu |
| Botanix Sb INC | $18.29 | 2025 | Sofdra |
| Almirall LLC | $16.88 | 2025 | Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.83 | 2024 | Cabtreo |
| Krystal Biotech INC | $15.19 | 2025 | Vyjuvek |
| Verrica Pharmaceuticals INC. | $14.46 | 2023 | Ycanth |
| Blueprint Medicines Corporation | $13.20 | 2024 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yi Lai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.